Clinical Outcomes of CD7 CAR‐T Cell Therapy in Relapsed or Refractory T‐Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Patients
Sign Up to like & getrecommendations! Published in 2025 at "Hematological Oncology"
DOI: 10.1002/hon.70081
Abstract: Relapse and refractory T‐cell acute lymphoblastic leukemia and lymphoblastic lymphoma (R/R T‐ALL/LBL) patients have poor outcomes. Chimeric antigen receptor (CAR)‐T‐cell therapy for T‐ALL/LBL has shown encouraging results in the early stages of clinical trials. Here,… read more here.
Keywords: cell therapy; allo hsct; car cell; car ... See more keywords
CD7 chimeric antigen receptor T cells for relapsed/refractory T-cell lymphomas: Single-arm, open-label, phase I study
Sign Up to like & getrecommendations! Published in 2025 at "Blood"
DOI: 10.1182/blood-2025-2368
Abstract: Background: The prognosis of refractory/relapsed T-cell lymphoma is extremely poor, especially for the patients who failed to allogeneic hematopoietic stem cell transplantation(alloHSCT). Aims: In this single-center Phase I study (ChiCTR2200058969), we administered CD7 CAR T… read more here.
Keywords: car; cell; car cells; cd7 car ... See more keywords
Donor-derived CD7 CAR T cells for T-cell acute lymphoblastic leukemia.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2021.39.15_suppl.10001
Abstract: 10001 Background: Despite the success of chimeric antigen receptor T cell therapy in B cell malignances, there is currently no proved CAR T treatment for T cell neoplasms. We provide first evidence support the use… read more here.
Keywords: car cells; cd7 car; donor derived; car ... See more keywords
Potential benefits of using a different donor for transplantation consolidation after donor-derived CD7 CAR T.
Sign Up to like & getrecommendations! Published in 2025 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2025.43.16_suppl.6536
Abstract: 6536 Background: Stem cell transplantation (SCT) is often used in patients with relapsed or refractory T-cell acute lymphoblastic leukemia (r/r T-ALL) after CD7 CAR T therapy, in order to consolidate efficacy or promote immune reconstitution… read more here.
Keywords: sct; trial; group; consolidation ... See more keywords
Targeted CD7 CAR T-cells for treatment of T-Lymphocyte leukemia and lymphoma and acute myeloid leukemia: recent advances
Sign Up to like & getrecommendations! Published in 2023 at "Frontiers in Immunology"
DOI: 10.3389/fimmu.2023.1170968
Abstract: The high expression of CD7 targets in T-cell acute lymphoblastic leukemia (T-ALL) and T-lymphoma has attracted considerable attention from researchers. However, because CD7 chimeric antigen receptor (CAR) T-cells undergo fratricide, CD7 CAR T-cells develop an… read more here.
Keywords: leukemia lymphoma; car; cd7 car; car cells ... See more keywords
Case report: The case of T-cell acute lymphoblastic leukemia treated with chemotherapy followed by anti-CD7 CAR-T cells using retroviral vector
Sign Up to like & getrecommendations! Published in 2025 at "Frontiers in Immunology"
DOI: 10.3389/fimmu.2024.1519055
Abstract: CD7-targeted chimeric antigen receptor-T (CAR-T) cell therapy has shown great promise in the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia (T-ALL). In this study, we reported a case of a 34-year-old male patient with T-ALL… read more here.
Keywords: anti cd7; car; case; car cells ... See more keywords
The efficacy and safety of CD7 chimeric antigen receptor T-cell therapy for hematologic malignancies: a systematic review and meta-analysis
Sign Up to like & getrecommendations! Published in 2025 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2024.1478888
Abstract: Introduction CD7 chimeric antigen receptor T-cell (CAR-T cell) therapy is an emerging method for treating hematological malignancies, and is another breakthrough in CAR-T cell therapy. Methods This study summarizes the currently published clinical research results… read more here.
Keywords: cell therapy; car cell; car; cell ... See more keywords